MECHANISMS BY WHICH IFN-GAMMA SEPARATES GVHD AND GVL
IFN-γ 分离 GVHD 和 GVL 的机制
基本信息
- 批准号:7158088
- 负责人:
- 金额:$ 17.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:antigen antibody reactionantineoplasticsapoptosiscell migrationcell proliferationclinical researchcytotoxic T lymphocytedisease /disorder modelgraft versus host diseasehematopoietic tissue transplantationhomologous transplantationinterferon gammaintravital microscopylaboratory mouseleukemialeukocyte activation /transformationmodel design /developmentmolecular dynamicsmonoclonal antibodynatural killer cellsneoplasm /cancer radiation therapynonhuman therapy evaluationstem cell transplantationtissue donorstransfection
项目摘要
The inability to selectively prevent GVHD without diminishing graft-vs.-leukemia (GVL) effects limits the
success of clinical allogeneic hematopoietic cell transplantation (allo-HCT), an effective therapy for the
treatment of many otherwise fatal hematologic malignancies. CD8 T cells are major effector cells that
induce both GVHD and GVL effects after allo-HCT. Our previous studies using anti-IFN-gamma mAb and
IFN-gamma-deficient mice showed that IFN-gamma restricts donor CD8 T cell activation/expansion through
induction of apoptosis and inhibits mononuclear cell infiltration in parenchymal GVHD target tissues in
recipients of CD4-depleted allo-HCT, and that donor CD8 T cells induce more severe GVHD but less
potent anti-lymphohematopoietic GVH reactions and GVL effects in the absence of IFN-gamma. The goal of
this project is to understand the mechanisms by which IFN-gamma regulates the alloreactivity of donor CDS T
cells as a prerequisite to the development of approaches that can induce GVL effects without severe
GVHD. In Aim 1, we will determine whether or not IFN-gamma restricts expansion of both recipient antigen-specific
and -nonspecific (homeostatic proliferation) donor CDS T cells, and identify the mechanisms
responsible for IFN-gamma-induced apoptosis of donor CDS T cells in allo-HCT recipients. In Aim 2, we will
test the hypothesis that IFN-gamma suppresses the migration, in-situ proliferation and/or survival of donor
CDS T cells in parenchymal GVHD target tissues and thereby inhibits GVHD while preserving GVL
effects. In Aim 3, we will determine how IFN-gamma mediates GVL effects without promoting GVHD. We will:
1) develop IFN-gamma-unresponsive leukemia models to determine whether or not IFN-gamma can enhance GVL
effects by inhibiting tumor cell proliferation and/or sensitizing tumor cells to alloreactive CTLs; 2)
assess the role of IFN-gamma in the differentiation of alloreactive CTLs with different cytotoxic mechanisms
and the contribution of these cytotoxic mechanisms to the induction of GVHD vs. GVL effects in the
presence and absence of IFN-gamma; and 3) determine the role of NK and NKT cells in the induction of GVL
effects. Achieving these aims will lead to a better understanding of mechanisms involved in GVHDand
GVL-associated alloreactivity of CDS T cells and facilitate the development of novel protocols for
the performance of HLA-mismatched allo-HCT in the clinic. In addition to highly-relevant hypotheses to
be addressed, collaborative interactions within the PPG can also be established based on the models
developed in this project.
在不减弱移植物抗白血病(GVL)效应的情况下选择性地预防GVHD的能力限制了
临床异基因造血细胞移植(allo-HCT)的成功,是治疗慢性粒细胞白血病的一种有效方法
治疗许多其他致命的血液系统恶性肿瘤。CD8 T细胞是主要的效应细胞
在allo-HCT后同时引起GVHD和GVL效应。我们之前的研究使用了抗干扰素-γ单抗和
干扰素-γ缺陷小鼠显示干扰素-γ通过以下途径限制供者CD8 T细胞的激活/扩增
诱导GVHD大鼠实质靶组织细胞凋亡及抑制单个核细胞侵袭
接受CD4耗尽的allo-HCT的受者,供者CD8T细胞会引起更严重的GVHD,但更少
在没有干扰素-γ的情况下,有效的抗淋巴造血GVH反应和GVL效应。的目标是
本项目旨在了解干扰素-γ调节供者CDS-T同种异体反应性的机制。
细胞作为开发方法的先决条件,可以在不严重的情况下诱导GVL效应
GVHD。在目标1中,我们将确定干扰素-γ是否限制两种受体抗原特异性的扩增
和-非特异性(内稳态增殖)供体CDS T细胞,并确定其机制
负责干扰素-γ诱导allo-HCT受者供者CDS T细胞的凋亡。在目标2中,我们将
验证干扰素-γ抑制供者迁移、原位增殖和/或存活的假说
CDS T细胞在实质GVHD靶组织中的作用,从而在保留GVL的同时抑制GVHD
效果。在目标3中,我们将确定干扰素-γ如何在不促进GVHD的情况下介导GVL效应。我们会:
1)建立干扰素-γ无反应性白血病模型,以确定干扰素-γ是否能增强GVL
通过抑制肿瘤细胞增殖和/或使肿瘤细胞对同种异体反应性CTL增敏来发挥作用;2)
干扰素-γ在不同细胞毒机制的同种异体反应性CTL分化中的作用
以及这些细胞毒机制在GVHD和GVL效应的诱导中的作用
3)确定NK细胞和NKT细胞在GVL诱导中的作用
效果。实现这些目标将有助于更好地理解全球变暖和
GVL相关CDS T细胞的同种异体反应并促进新方案的开发
人类白细胞抗原不全相合异基因红细胞移植的临床应用除了高度相关的假设外,
因此,PPG内的协作交互也可以基于模型来建立
在这个项目中开发的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YONG-GUANG YANG其他文献
YONG-GUANG YANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YONG-GUANG YANG', 18)}}的其他基金
Immune response to allogeneic hESC-derived endothelial cells
对同种异体 hESC 衍生内皮细胞的免疫反应
- 批准号:
7826527 - 财政年份:2010
- 资助金额:
$ 17.75万 - 项目类别:
Role of CD47 in xenograft rejection by macrophages
CD47 在巨噬细胞异种移植排斥中的作用
- 批准号:
8622183 - 财政年份:2007
- 资助金额:
$ 17.75万 - 项目类别:
Role of CD47 in xenograft rejection by macrophages
CD47 在巨噬细胞异种移植排斥中的作用
- 批准号:
8110295 - 财政年份:2007
- 资助金额:
$ 17.75万 - 项目类别:
Role of CD47 in xenograft rejection by macrophages
CD47 在巨噬细胞异种移植排斥中的作用
- 批准号:
7741758 - 财政年份:2007
- 资助金额:
$ 17.75万 - 项目类别:
Role of CD47 in xenograft rejection by macrophages
CD47 在巨噬细胞异种移植排斥中的作用
- 批准号:
7373273 - 财政年份:2007
- 资助金额:
$ 17.75万 - 项目类别:
Role of CD47 in xenograft rejection by macrophages
CD47 在巨噬细胞异种移植排斥中的作用
- 批准号:
8236477 - 财政年份:2007
- 资助金额:
$ 17.75万 - 项目类别:
Role of CD47 in xenograft rejection by macrophages
CD47 在巨噬细胞异种移植排斥中的作用
- 批准号:
8436181 - 财政年份:2007
- 资助金额:
$ 17.75万 - 项目类别:
Role of CD47 in xenograft rejection by macrophages
CD47 在巨噬细胞异种移植排斥中的作用
- 批准号:
7535173 - 财政年份:2007
- 资助金额:
$ 17.75万 - 项目类别:
Role of CD47 in xenograft rejection by macrophages
CD47 在巨噬细胞异种移植排斥中的作用
- 批准号:
7989143 - 财政年份:2007
- 资助金额:
$ 17.75万 - 项目类别:
相似海外基金
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
新型底物竞争性 Bcr-Abl 抑制剂对格列卫耐药 CM 具有活性
- 批准号:
7046281 - 财政年份:2006
- 资助金额:
$ 17.75万 - 项目类别:
Targeted Therapy of Lyn in Myelodysplastic Syndrome
Lyn 治疗骨髓增生异常综合征的靶向治疗
- 批准号:
7034786 - 财政年份:2006
- 资助金额:
$ 17.75万 - 项目类别:
Analysis of Patient Tumor Responses to Apo2L/TRAIL
患者肿瘤对 Apo2L/TRAIL 的反应分析
- 批准号:
7034793 - 财政年份:2006
- 资助金额:
$ 17.75万 - 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
- 批准号:
7033212 - 财政年份:2006
- 资助金额:
$ 17.75万 - 项目类别:
Proapoptotic Therapy for B-cell Non Hodgkin's Lymphoma
B 细胞非霍奇金淋巴瘤的促凋亡治疗
- 批准号:
7056286 - 财政年份:2006
- 资助金额:
$ 17.75万 - 项目类别:
Novel beta-Lactams as New Anti-Cancer Agents
新型 β-内酰胺作为新型抗癌药物
- 批准号:
7163260 - 财政年份:2006
- 资助金额:
$ 17.75万 - 项目类别:
Dysfunctional Telomeres, Checkpoints and Aging
功能失调的端粒、检查点和衰老
- 批准号:
7065017 - 财政年份:2006
- 资助金额:
$ 17.75万 - 项目类别:
Inhibition of Bcl-2 and Head & Neck Tumor Angiogenesis
Bcl-2 和 Head 的抑制
- 批准号:
6903214 - 财政年份:2005
- 资助金额:
$ 17.75万 - 项目类别:
Predicting Melanoma Response to BAY 43-9006/Chemotherapy
预测黑色素瘤对 BAY 43-9006/化疗的反应
- 批准号:
6955905 - 财政年份:2005
- 资助金额:
$ 17.75万 - 项目类别:














{{item.name}}会员




